Article

Quiz: Best Practices for Corticosteroid Use in Active Rheumatoid Arthritis

Author(s):

Glucocorticoids are the most frequently used class of drugs for rheumatoid arthritis because they are effective at relieving symptoms, and widely available at low cost. While this drug class has clear benefits for rheumatoid arthritis, it comes at a price in terms of a wide array of potential side-effects. Test your knowledge on the use of corticosteroids in rheumatoid arthritis with this quiz.

Glucocorticoids are the most frequently used class of drugs for rheumatoid arthritis (RA) because they are effective at relieving symptoms, and widely available at low cost. While this drug class has clear benefits for rheumatoid arthritis, it comes at a price in terms of a wide array of potential side-effects. Test your knowledge on the use of corticosteroids in rheumatoid arthritis with this quiz.

1) Which of the following statements align with the 2015 American College of Rheumatology guidelines regarding the use of corticosteroids in patients with rheumatoid arthritis?

a) For the treatment of early rheumatoid consider add low-dose glucocorticoids (≤10 mg/day of prednisone or equivalent) in patients with moderate or high disease activity when starting disease-modifying antirheumatic drugs (DMARDs) or where DMARD or biologics have failed to control disease activity.

b) Short courses of low dose corticosteroids (≤10 mg/day of prednisone or equivalent) may be used first line in patients with early RA with only mild symptoms.

c) Consider using short-term glucocorticoids (up to 3 months) for disease flares.

d) For patients with advanced disease higher doses of corticosteroids may be needed to control flares

e) The risk/benefit ratio of glucocorticoid therapy is unfavorable for most patients with rheumatoid arthritis

f) Glucocorticoids should be used at the lowest possible dose and for the shortest possible duration

g) The target should ideally be low disease activity or remission.


 

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.